Actionable insights on equities, fixed-income, macros and personal finance Start 14-Days Free Trial
Actionable investing insights Get Free Trial

Capsule – 18/01: Vijay Kishanlal Kedia buys Karnataka Bank, Jayantilal Patel buys battered Lincoln Pharma and Forefront Capital Management buys McNally Bharat Engineering


Here is the “Capsule” of the data that is revealed in the markets. This has been collated and curated to make trade-able sense.

Bulk & Block Deals

Here is a summary of Bulk & Block Deal transactions in this week. A Bulk Deal is a trade, where total quantity bought or sold is more than 0.5% of the number of equity shares of the company. A trade, with a minimum quantity of 5,00,000 shares or minimum value of Rs.5 crore executed through a single transaction on this separate window of the stock exchange will constitute a Block Deal. (Capsule for 15-Jan-16Capsule for 13-Jan-16Capsule for 11-Jan-16Capsule for 8-Jan-16Capsule for 6-Jan-16Capsule for 5-Jan-16Capsule for 4-Jan-16)


Karnataka Bank

Karnataka Bank Limited, a leading ‘A’ Class Scheduled Commercial Bank in India, was incorporated on February 18th, 1924 at Mangaluru, a coastal town of Dakshina Kannada district in Karnataka State. The bank took shape in the aftermath of patriotic zeal that engulfed the nation during the freedom movement of 20th Century India. Over the years the Bank grew with the merger of Sringeri Sharada Bank Ltd., Chitradurga Bank Ltd. and Bank of Karnataka.

The total business turnover of the Bank was 81,315 crores as on 30-Sep-2015, registering a y-o-y growth of 10.01%. Deposits of the Bank rose to 48,872 crores registering a y-o-y growth of 10.58%. Advances rose to 32,443 crores registering a y-o-y growth of 9.17%.

Kedia Securities purchased 1,000,000 shares or 0.53% at an avg. price of Rs. 99.32/- per share. This values the deal at Rs. 993 lakhs.

Kedia Securities is run by Big Whale Vijay Kishanlal Kedia.

Other Investors include Life Insurance Corporation of India, Goldman Sachs, Government Pension Fund Global, LSV Emerging Markets Equity FundCredit Suisse and others.

In the news: Karnataka Bank posted a Net Profit of Rs. 309 Crores in Q3-2015

Lincoln Pharma

Established in 1979 to manufacture and market affordable therapeutic products. The company has its own manufacturing facilities, covering all the major dosage forms, like tablets, capsules, injectables, syrups, Ointments, etc. Its present manufacturing activities are located near Ahmedabad. The plant spreads across 30,000 square meters. There are three different buildings for tablets, capsules and injectables and also a separate building for quality control.

An ultramodern laboratory with state–of–the–art equipments ensures in–house quality assurance of each of the products. The products are designed for all therapeutic segments with a special emphasis on gynecological and orthopedic specialties.

Products of the company – Tablets, Capsules, Injectables, Syrups, Ointments

Certification – WHO–GMP standard, ISO 9002 certification , Export House certification

The recently NSE listed stock on 17-Dec-15, opened at Rs. 215.00/- only to climb up to Rs. 305.45/- by 6-Jan-16.


The stock got battered today as the stock fell to its lowest low of Rs. 179.25/- and was locked in lower circuit after the company said that Tanzania drug authority (TFDA) has announced to stop and banned importing of Chloramphenicol Sodium Succinate Injection and also cancelled the company’s registration.

In this circumstance a huge quantity dispatched by the company to Tanzania has kept on hold there and authority has issued a notice to destroy the product. Also due to the rejection of registration, a large number of raw materials and packaging material stock is piled up at factory, and this creates an addition to the loss amount.

Chloramphenicol Sodium Succinate Injection is one of the company’s highest selling products and has got many orders from the government institutes.

Jayantilal D Patel – an individual investor purchased 162,278 shares or 1% of the shareholding. This was purchased at an avg. price of Rs. 183.02/- per share, thereby valuing the deal at Rs. 297 lakhs.

Further shareholding details available here

McNally Bharat Engineering

Leading Engineering Companies in India engaged in providing turnkey solutions in the areas of Power, Steel, Aluminium, Material Handling, Mineral Beneficiation, Pyro-processing, Pneumatic Handling of powdered materials including fly ash handling and high concentrate disposal, coal washing, Port cranes, Cement, Oil & Gas, civic and industrial water supply etc.

Forefront Capital Management which sold 220,616 shares on 6-Jan-16 (check out the Capsule), today purchased 334,052 shares or 0.66% thereby valuing the deal at Rs. 331 lakhs.


Delivery Volume Shockers!

We have compiled a list of those stocks which have seen massive increases in the “deliverable quantity to traded quantity %”.

Stocks are traded every day and most stocks see intra-day trading (buy and sell on the same day). Intra-day trades don’t result in delivery – if two people buy and sell from each other and square off within the day, there will be volume, but no actual shares will change hands.

Delivery volumes as a percentage of total volume shows us how much of the stock is traded versus held for more than a day. It’s not very useful to use this data to trade per se.

But what is useful is if the delivery percentage JUMPS. If a stock is thinly delivered (say 30% delivery) and jumps up to 80% delivery then we are likely to be seeing some action in that stock because either a big buyer is in or a big seller is.

Listed below, are the Top 25 for Friday (18th Jan, 2016):


 divider Next Gen Financial Analytics


Like our content? Join Capitalmind Premium.

  • Equity, fixed income, macro and personal finance research
  • Model equity and fixed-income portfolios
  • Exclusive apps, tutorials, and member community
Subscribe Now Or start with a free-trial